AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

NASDAQ:EIGREiger Biopharmaceuticals Stock Price, Forecast & News

$12.24
+0.27 (+2.26 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.89
Now: $12.24
$12.26
50-Day Range
$7.22
MA: $10.07
$13.37
52-Week Range
$4.55
Now: $12.24
$15.82
Volume363,674 shs
Average Volume365,713 shs
Market Capitalization$306.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Read More
Eiger Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.31 per share

Profitability

Net Income$-70,250,000.00

Miscellaneous

Employees18
Market Cap$306.69 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

How has Eiger Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eiger Biopharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EIGR shares have increased by 79.7% and is now trading at $12.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eiger Biopharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eiger Biopharmaceuticals.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Eiger Biopharmaceuticals.

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.76) by $0.14. View Eiger Biopharmaceuticals' earnings history.

What price target have analysts set for EIGR?

5 brokerages have issued 12 month price objectives for Eiger Biopharmaceuticals' stock. Their forecasts range from $10.72 to $33.00. On average, they expect Eiger Biopharmaceuticals' stock price to reach $24.18 in the next twelve months. This suggests a possible upside of 97.5% from the stock's current price. View analysts' price targets for Eiger Biopharmaceuticals.

What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (1/27/2020)
  • 2. LADENBURG THALM/SH SH analysts commented, "We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs." (8/12/2019)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

News headlines about EIGR stock have been trending very negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutEiger Biopharmaceuticals.

Who are some of Eiger Biopharmaceuticals' key competitors?

What other stocks do shareholders of Eiger Biopharmaceuticals own?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the following people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
  • Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
  • Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38)

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger Biopharmaceuticals' major shareholders?

Eiger Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.59%), Vivo Capital LLC (7.15%), Cormorant Asset Management LP (3.25%), State Street Corp (1.83%), Soleus Capital Management L.P. (1.62%) and P.A.W. Capital Corp (1.47%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View institutional ownership trends for Eiger Biopharmaceuticals.

Which major investors are selling Eiger Biopharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, JPMorgan Chase & Co., BlackRock Inc., Cormorant Asset Management LP, Morgan Stanley, New York State Common Retirement Fund, Victory Capital Management Inc., and Victory Capital Management Inc.. View insider buying and selling activity for Eiger Biopharmaceuticals.

Which major investors are buying Eiger Biopharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, P.A.W. Capital Corp, Soleus Capital Management L.P., Nuveen Asset Management LLC, Two Sigma Advisers LP, Voss Capital LLC, Two Sigma Investments LP, and Trellus Management Company LLC. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz. View insider buying and selling activity for Eiger Biopharmaceuticals.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $12.24.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $306.69 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.

What is Eiger Biopharmaceuticals' official website?

The official website for Eiger Biopharmaceuticals is www.eigerbio.com.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.